ArticleScientific reports2025
Inhibition effects of Eucalyptus globules Labill. essential oil against tyrosinase.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Seasonal Phytochemical Variation and Bioactivity of Artemisia herba-alba: Comparative Evaluation of Essential Oils and Phenolic Extracts With Antioxidant, Tyrosinase Inhibitory and In Silico Studies.Chemistry & biodiversity · 2026Article
- Polymer-Based Microencapsulation ofPharmaceutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Essential oils derived from Eucalyptus globules Labill. (EGEOs) represent a significant class of bioactive metabolites with broad applications in medicinal and pharmaceutical industries. Despite their various biological activities, the potential of EGEOs to inhibit tyrosinase, a key enzyme in melanin biosynthesis, remains unexplored. Then, this study delineates the inhibitory effects of EGEOs on tyrosinase. Our findings indicated that EGEOs acted as one reversible and non-competitive inhibitor toward tyrosinase, presenting an inhibition rate of 59.6% (10 mg/ml). Circular dichroism (CD) spectral analysis suggested that EGEOs induced conformational changes in tyrosinase, potentially disrupting its catalytic function. The binding of EGEOs to tyrosinase, as evidenced by ANS binding assays, led to the exposure of hydrophobic regions within the enzyme, further impairing its activity. Molecular docking studies illustrated the specific interactions between the major metabolite of EGEOs, 1,8-cineole, and tyrosinase. Moreover, the impact of EGEOs on melanin production was assessed in B16F10 melanoma cells, demonstrating a significant reduction in intracellular melanin content upon EGEOs treatment. Collectively, these results suggested EGEOs as one promising natural tyrosinase inhibitor with potential applications in treating hyperpigmentation and associated skin disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.